Strengthening the EU Blood Directive for patients who need plasma-derived medicines

The revision of the European Union Blood, Tissues and Cells (BTC) Legislation brings an opportunity to strengthen its legal framework to encourage new approaches that will increase the collection of plasma across Europe.

A renewed EU BTC legislation should clarify plasma’s unique aspects, highlight the differences between plasma, whole blood, and other blood components and allow the co-existence of the public and private sectors. Watch the video to learn more

Subscribe to our newsletters